Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Amcad BiomedROCO:4188 +2.85%50 Return-on-Tangible-Asset is -10.91% as of Jun. 2026. GuruFocus rates ROCO:4188 with a GF Score™ of 50/100 and a GF Value™ of NT$9.62 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 852 Medical Devices & Instruments companies, Amcad Biomed ranks worse than 64.44% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Amcad Biomed's annualizedNet Income for the quarter that ended in Jun. 2026 was NT$-60.45 Mil. Amcad Biomed's average total tangible assets for the quarter that ended in Jun. 2026 was NT$554.16 Mil. Therefore, Amcad Biomed's annualized Return-on-Tangible-Asset for the quarter that ended in Jun. 2026 was -10.91%.
The historical rank and industry rank for Amcad Biomed's Return-on-Tangible-Asset or its related term are showing as below:
ROCO:4188'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -10.73 Med: -9.04 Max: -4.71
Current: -9.31
During the past 13 years, Amcad Biomed's highest Return-on-Tangible-Asset was -4.71%. The lowest was -10.73%. And the median was -9.04%.
ROCO:4188's Return-on-Tangible-Asset is ranked worse than 64.44% of 852
companies
in the Medical Devices & Instruments industry
Industry Median: 0.925
vs ROCO:4188: -9.31
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Amcad Biomed Return-on-Tangible-Asset Related Terms
Amcad Biomed Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Amcad Biomed's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:4188 vs ABT, SYK, MDT: Return-on-Tangible-Asset Comparison
For the Medical Devices subindustry, Amcad Biomed's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Amcad Biomed Return-on-Tangible-Asset vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Amcad Biomed's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Amcad Biomed's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Jun. 2026) net income data.
What does a Return-on-Tangible-Asset of -10.91% mean?
Amcad Biomed (ROCO:4188) has a Return-on-Tangible-Asset of -10.91% as of Jun. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Amcad Biomed and its competitors. According to the industry distribution chart, Amcad Biomed ranks #549 out of 852 companies in the Medical Devices & Instruments industry, placing it in the top 64.4%.
Is Amcad Biomed's Return-on-Tangible-Asset too high?
Amcad Biomed's current Return-on-Tangible-Asset is -10.91%. Based on the distribution chart, Amcad Biomed ranks #549 out of 852 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Amcad Biomed has a GF Score™ of 50/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Amcad Biomed's Return-on-Tangible-Asset compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Amcad Biomed ranks #549 out of 852 companies for Return-on-Tangible-Asset. This places Amcad Biomed in the lower half of its industry. The industry median Return-on-Tangible-Asset is 0.93. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Medical Devices & Instruments company?
The median Return-on-Tangible-Asset among Medical Devices & Instruments companies is 0.93, based on 852 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Amcad Biomed and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Asset is 0.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Amcad Biomed's current Return-on-Tangible-Asset is -10.91%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amcad Biomed stock overvalued right now?
Based on GuruFocus' analysis, Amcad Biomed (ROCO:4188) is currently considered Significantly Overvalued. The stock's GF Value™ is NT$9.62, compared to a current price of NT$14.45 — trading 50.2% above its estimated fair value. The current Return-on-Tangible-Asset is -10.91%. Amcad Biomed's overall GF Score™ is 50/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Amcad Biomed (ROCO:4188), the current Return-on-Tangible-Asset is -10.91% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Amcad Biomed (ROCO:4188) Overvalued in 2026?
Based on GuruFocus' analysis, Amcad Biomed stock appears to be overvalued.
The current stock price of NT$14.45 is trading 50.2% above its estimated GF Value™ of NT$9.62.
GuruFocus considers Amcad Biomed to be Significantly Overvalued.
Key valuation signals for ROCO:4188:
Return-on-Tangible-Asset: -10.91%
GF Value™: NT$9.62 vs. price of NT$14.45 (50.2% above fair value)
No single metric tells the full story. See the ROCO:4188 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Amcad Biomed Corp develops computer-aided detection and diagnosis(CADe/CADx) software devices. Its product pipeline includes AmCAD-UT Detection, AmCAD-UV, AmCAD and AmCAD-UO. Geographically, the company generates revenue from Taiwan, China, Europe, Asia (excluding Taiwan and China), and other countries, out of which the majority of the revenue is generated from Taiwan. The company has two segments: the Medical Diagnostic Software segment, which is responsible for the development and sales of smart medical imaging diagnostic software devices, and the Precision Medical Equipment segment, which is responsible for research, development, manufacturing, and sales of high-end ultrasonic probes. The company generates the majority of its revenue from the Precision Medical Equipment segment.
50GF Score
Get the complete analysis for ROCO:4188
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4188 has been successfully added to your 
